

# ASX Announcement

23 September 2021



## AnteoTech Signs Romanian Distribution Agreement for EuGeni

### Highlights

- ❖ **Eromediks Aparatura Medicala to become the exclusive EuGeni distributor in Romania**
- ❖ **Distributor Agreements for EuGeni now in place in 14 countries**

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to advise that it has today signed a Distribution Agreement (Agreement) with Eromediks Aparatura Medicala (Eromediks) for the distribution of the EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT)<sup>1</sup> in Romania.

Eromediks was founded in 2006, as an importer and distributor of a wide range of medical laboratory equipment.

The CE Marking of the EuGeni Reader and test enable market access in Romania after registration with the National Agency for Medicines and Medical Devices Romania (NAMMD). AnteoTech will be applying for registration with the NAMMD in the coming weeks.

**AnteoTech CEO Derek Thomson said,** "We are delighted to welcome the team at Eromediks to the EuGeni and AnteoTech family. Eromediks have a history of distributing quality reader based diagnostics in the Romanian market and the addition of EuGeni will provide a high quality rapid diagnostic platform to their stable of products. Eromediks further expands our presence in Europe and is another clear endorsement of AnteoTech's initiative to provide a suite of qualitative and quantitative tests, superior performance, data capability, and ease of use in a rapid testing platform."

### Key terms of the Agreement:

- The Agreement commences effective 1 October 2021. There are no conditions precedent to the Agreement.
- The Agreement is for exclusive sales into Romania
- The initial term of the distribution agreement is for three years, renewable for a further two years after the initial term on mutual agreement.

<sup>1</sup> The AnteoTech Antigen Rapid Diagnostic Test detects the SARS-CoV-2 virus that causes the disease called COVID-19

- Government or large enterprise tender opportunities: AnteoTech and Eromediks will work together to assess each tender opportunity on a case-by-case basis.
- In addition to the terms outlined in this announcement, the Agreement is subject to the standard terms, conditions, and warranties typical of a contract of this type. AnteoTech has the right to terminate the Agreement with immediate effect upon the breach or non-observance of any of the terms and conditions contained in the Agreement.

This announcement has been authorised for release by the Board.

**For more information, please contact:**

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

**EROMEDIKS APARATURA MEDICALA**

Eromediks, are based in Bucharest Romania, and were founded in 2006, as an importer and distributor of a wide range of medical laboratory equipment.

**ABOUT ANTEO GROUP – AnteoTech Ltd (ASX:ADO)**

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

Follow AnteoTech on Twitter: <https://twitter.com/AnteoTech> or visit [www.anteotech.com](http://www.anteotech.com)

